Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Evernorth is a subsidiary of The Cigna Group (NYSE:CI).
Evernorth Health Services週四表示，其Accredo分支機構將向患者提供Humira生物仿製藥，無需自付費用。埃弗諾斯是信諾集團（紐約證券交易所代碼：CI）的子公司。
Beginning in June, the high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private-label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with multiple manufacturers.
從6月開始，通過與多家制造商的協議，將爲Evernorth的附屬自有品牌藥品分銷商Qualent Pharmicals生產高濃度和低濃度可互換的生物仿製藥。
Most patients will be able to secure the biosimilar products for $0 out-of-pocket through the copay assistance programs offered at Quallent beginning in June, Evernorth said.
埃弗諾斯說，從6月開始，通過Quallent提供的自付額援助計劃，大多數患者將能夠以0美元的價格獲得生物仿製藥產品。
This program is estimated to save individual patients around $3,500 on average per year.
據估計，該計劃平均每年可爲個體患者節省約3500美元。
According to the announcement, the biosimilar price is about 85% lower than that of branded Humira. More than 100,000 Accredo patients use either Humira or one of its biosimilars, the company said.
根據公告，生物仿製藥的價格比品牌Humira的價格低約85％。該公司表示，超過10萬名Accredo患者使用Humira或其一種生物仿製藥。
The specialty pharmacy provides patients with a Therapeutic Resource Center to connect to specialty-trained pharmacists and nurses who are available around the clock. Accredo's centers cover 15 specific conditions.
該專業藥房爲患者提供治療資源中心，可與經過專業培訓的藥劑師和護士建立聯繫，這些藥劑師和護士全天候待命。Accredo 的中心涵蓋 15 種特定條件。
Humira is AbbVie Inc's (NYSE:ABBV) blockbuster arthritis drug. In the most recent first-quarter earnings, Humira generated sales of $2.27 billion (down 35.9% Y/Y).
Humira是艾伯維公司（紐約證券交易所代碼：ABBV）的重磅關節炎藥物。在最新的第一季度業績中，Humira創造了22.7億美元的銷售額（同比下降35.9％）。
Reuters notes that AbbVie has held onto more than 98% of the Humira market despite nine biosimilars being launched in the U.S. last year.
路透社指出，儘管去年在美國推出了九種生物仿製藥，但艾伯維仍佔據了Humira市場98％以上的份額。
Citing IQVIA data, Reuters highlighted that privately-held German drugmaker Boehringer launched its version, Cyltezo, last July but has only sold a couple of thousand prescriptions since then.
路透社援引IQVIA的數據，強調私人控股的德國製藥商勃林格於去年7月推出了其版本Cyltezo，但此後僅售出了幾千張處方。
Reuters report added that almost 3 million Humira prescriptions have been written during the same period, although tens of thousands of scripts have started to shift to biosimilar Hyrimoz each week since CVS Health's Inc (NYSE:CVS) pharmacy benefits unit took Humira off the list of drugs it recommends insurers reimburse.
路透社的報道補充說，儘管自CVS Health's Inc（紐約證券交易所代碼：CVS）藥房福利部門將Humira從其建議保險公司報銷的藥物清單中刪除以來，每週都有成千上萬張Humira處方開始轉向生物仿製藥Hyrimoz，但同期已經開出了近300萬張Humira處方。
Price Action: CI shares are down 0.07% at $354.25 at the last check Friday.
價格走勢：在週五的最後一次檢查中，CI股價下跌0.07％，至354.25美元。
Image: Phoenix Locklear from Pixabay
圖片：來自 Pixabay 的菲尼克斯·洛克利爾